Novel approaches in GVHD therapy

被引：8

作者：

Svennilson, J ^{[1
]}

机构：

[1] Karolinska Inst, Huddinge Hosp, Ctr Allogeneic Stem Cell Transplantat, S-14186 Stockholm, Sweden

[2] Karolinska Inst, Huddinge Hosp, Paediat Haematol Unit, S-14186 Stockholm, Sweden

来源：

BONE MARROW TRANSPLANTATION | 2005年 / 35卷 / Suppl 1期

关键词：

children; graft-versus-host disease; immunosuppression; mesenchymal stem cells;

D O I：

10.1038/sj.bmt.1704850

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Severe graft-versus-host disease is a lethal complication to allogeneic haemopoietic stem cell transplantation. This short review gives an overview of novel treatment strategies. Psoralen-enhanced UVA irradiation ( PUVA), extracorpoal PUVA, antibodies against IL-2 and TNF-alpha, thalidomide, octreotide, and mesenchymal stem cells are briefly discussed.

引用

页码：S65 / S67

页数：3

共 18 条

[1] Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
Arora, M
Wagner, JE
Davies, SM
Blazar, BR
Defor, T
Enright, H
Miller, WF
Weisdorf, DJ
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (05) : 265 - 273
[2] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
Bartholomew, A
Sturgeon, C
Siatskas, M
Ferrer, K
McIntosh, K
Patil, S
Hardy, W
Devine, S
Ucker, D
Deans, R
Moseley, A
Hoffman, R
[J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) : 42 - 48
[3] THE SOMATOSTATIN ANALOG OCTREOTIDE IN THE MANAGEMENT OF THE SECRETORY DIARRHEA OF THE ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE IN A PATIENT AFTER BONE-MARROW TRANSPLANTATION
BIANCO, JA
HIGANO, C
SINGER, J
APPELBAUM, FR
MCDONALD, GB
[J]. TRANSPLANTATION, 1990, 49 (06) : 1194 - 1195
[4] ELY P, 1991, AM J MED, V90, P707
[5] Greinix HT, 2000, BLOOD, V96, P2426
[6] Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies
Ippoliti, C
Champlin, R
Bugazia, N
Przepiorka, D
Neumann, J
Giralt, S
Khouri, I
Gajewski, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (11) : 3350 - 3354
[7] Anti-cytokine therapy for the treatment of graft-versus-host disease
Jacobsohn, DA
Vogelsang, GB
[J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (11) : 1195 - 1205
[8] Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody
Kobbe, G
Schneider, P
Rohr, U
Fenk, R
Neumann, F
Aivado, M
Dietze, L
Kronenwett, R
Hünerlitürkoglu, A
Haas, R
[J]. BONE MARROW TRANSPLANTATION, 2001, 28 (01) : 47 - 49
[9] Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease
Kulkarni, S
Powles, R
Sirohi, B
Treleaven, J
Saso, R
Horton, C
Atra, A
Ortin, M
Rudin, C
Goyal, S
Sankpal, S
Meller, S
Pinkerton, CR
Mehta, J
Singhal, S
[J]. BONE MARROW TRANSPLANTATION, 2003, 32 (02) : 165 - 170
[10] Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc, K
Rasmusson, I
Sundberg, B
Götherström, C
Hassan, M
Uzunel, M
Ringdén, O
[J]. LANCET, 2004, 363 (9419) : 1439 - 1441

← 1 2 →